Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BNT162b2

- PMLiVE

Pfizer/BioNTech initiate study of first mRNA shingles vaccine candidates

Around 95% of people over the age of 50 have been exposed to the virus that causes shingles

- PMLiVE

Eiger BioPharmaceuticals reports positive phase 3 results for COVID-19 treatment

Peginterferon lambda showed a 51% reduction in hospitalisations or emergency room visits

- PMLiVE

NHS urges people yet to receive their COVID-19 booster to come forward

Sunday 12 February is the last day people under 50 years of age who are not considered at risk can receive a booster

- PMLiVE

JCVI recommends autumn COVID-19 vaccine booster for those at highest risk

After high uptake for the initial booster dose in December 2021, further uptake has been low

- PMLiVE

Pfizer expands low-cost medicine and vaccine programme to include off-patent products

The company will now offer 500 products to 45 lower-income countries on a not-for-profit basis

- PMLiVE

World Health Organization releases latest set of COVID-19 guidelines

The guidelines include advice on treatments, isolation periods and wearing masks

- PMLiVE

FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine

Preliminary data showed a possible link between the updated vaccine and a higher risk of stroke

- PMLiVE

Moderna and CytomX to partner in deal worth up to 1.2bn

The companies plan to develop mRNA-based therapies for a wide range of diseases

- PMLiVE

Pfizer and Gero collaborate on fibrotic disease research

The companies will use data to identify genes and pathways linked to fibrotic diseases

- PMLiVE

GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates

The vaccines produced promising preliminary results in phase 1 trials

- PMLiVE

WHO reports new Omicron subvariant cases detected in 29 countries worldwide

The new Omicron subvariant is spreading rapidly in the US

- PMLiVE

Valneva reports additional data for COVID-19 booster

VLA2001 was well tolerated in participants previously vaccinated with an mRNA vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links